LPLisa Pascopella

Lisa Pascopella

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa Pascopella has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Flood

    Tuberculosis Control Branch, Division of Communicable Disease Control , Center for Infectious Diseases, California Department of Public Health , Richmond

    2 shared publications
  • Pennan M. Barry

    Tuberculosis Control Branch, California Department of Public Health, Richmond, California

    2 shared publications
  • Barry P. M.

    1 shared publication
  • C. H Nguyen

    Tuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond, California, <></>, Analysis Group, Los Angeles, California, USA,

    1 shared publication
  • Gianna Peralta

    Present Affiliation: Acute Disease Epidemiology Section, Georgia Department of Public Health, Georgia

    1 shared publication
  • Hendrickx F.

    1 shared publication

Latest Publications

  • A Cross-sectional Study of Patients With Extrapulmonary Tuberculosis and Normal Chest Radiographs — What Characteristics Were Associated With Sputum Culture Positivity?

    by Victoria Le, Lisa Pascopella, Janice Westenhouse, Pennan Barry

    Background: Recognizing pulmonary involvement in tuberculosis (TB) patients is necessary to prevent TB transmission. We describe frequency and characteristics of patients with extrapulmonary TB (EPTB), normal chest radiographs, and positive sputum culture. Methods: We analyzed data of patients ≥15 years of age with EPTB reported to the California TB registry during 2011–2017 with cultured sputum and normal chest radiographs using generalized linear modeling to estimate prevalence ratios associated with positive sputum culture. Demographic, behavioral, clinical characteristics, and testing were compared for patients with positive and negative sputum culture. Results: Of 1635 patients with EPTB and normal chest radiographs, 937 (57%) had sputum culture performed, and 127 (13%) patients had positive results for Mycobacterium tuberculosis complex. Patients with positive results were more likely to: be male, experience homelessness, use substances, have HIV, and have >1 disease site. Among 85 patients with HIV co-infection, 54% had positive culture results compared with 9.5% among 852 patients without HIV co-infection. Patients with EPTB in more than 1 site were also more likely to have a positive sputum culture. Conclusions: Culturing sputum from patients with EPTB identified pulmonary cases not detected by chest radiograph, particularly among patients with HIV or >1 disease site.


  • Open Access

    A systematic synthesis of direct costs to treat and manage tuberculosis disease applied to California, 2015

    by Peter Oh, Lisa Pascopella, Pennan M. Barry, Jennifer M. Flood

    The cost of treating and managing cases of active tuberculosis (TB) disease—from diagnosis to treatment completion—is needed by agencies working on public health budgets, resource allocation and cost-effectiveness analysis. Although components of TB costs have been published in the United States (US), no recent study has assessed overall costs for TB care and potential gaps. To systematically review the US literature for costs of treating and managing cases of active TB disease, adjust these costs to current (2015) values, and assess gaps. We quantified total direct costs—from the perspective of the health care payer—of the treatment and case management of active TB disease. Estimates were based on published figures in the US, and operational data of the California Department of Public Health. The average direct cost of treating and managing a TB case was $34,600 in 2015. The average cost of a multidrug-resistant TB case was $110,900. Health care spending for treating and case managing TB patients in California amounted to approximately $75.6 million for the 2133 new cases reported in 2015. Most published cost estimates were based on data from the 1990s. TB is resource-intensive to treat and manage. Our synthesis provides inputs for budgets and economic analyses. New studies to provide original cost data are needed to better reflect current clinical and public health practices.


  • Open Access

    Use of Nucleic Acid Amplification Tests in Tuberculosis Patients in California, 2010–2013

    by Gianna Peralta, Pennan Barry, Lisa Pascopella

    Background Nucleic acid amplification tests (NAATs) have been used as a diagnostic tool for tuberculosis in the United States for many years. We sought to assess NAAT use in TB patients in California during a period of time when NAAT availability increased throughout the world. Methods We conducted a retrospective review of surveillance data from 6,051 patients with culture-confirmed pulmonary TB who were reported to the California TB registry during 2010-2013. Results Only 2,336 of 6,051 (39%) TB patients had a NAAT for diagnosis prior to culture results. Although 90% (N=2,101) with NAAT had positive test results, 9% (N=217) had falsely negative NAAT results, and 0.8% (N=18) had indeterminate NAAT results. The median time from specimen collection to TB treatment initiation was shorter when NAAT was used (three vs. 14 days, p < 0.0001), and patients with a positive NAAT result initiated treatment earlier than patients with a falsely negative result (one vs. 11 days from NAAT report, pConclusions Increased use of NAATs in diagnosis of pulmonary TB could decrease the time to treatment initiation and consequently decrease transmission. However, differential use and access to NAAT may prevent full realization of NAAT benefits in California.


  • Factors associated with extended treatment among tuberculosis patients at risk of relapse in California

    by Qin, Hendrickx F., Barry P. M., Pascopella L.

    SETTING: California, United States.OBJECTIVE: To determine the frequency of tuberculosis (TB) patients at risk for relapse who received at least 9 months of anti-tuberculosis treatment (extended treatment) and to identify factors associated with not receiving extended treatment.DESIGN: We analyzed characteristics of culture-confirmed pulmonary TB patients reported to the California TB Registry during 2004–2009. Patients with cavities on initial chest radiograph and delayed culture conversion (70 days) were at ‘high risk of relapse', and anti-tuberculosis treatment of 270 days was ‘extended treatment'. We used a generalized linear model to identify independent risk factors for absence of extended treatment in the high risk of relapse group.RESULTS: Among 5680 TB patients, 483 (8.5%) were at high risk of relapse: 372 (77%) received extended treatment but 111 (23%) did not. Factors associated with absence of extended treatment included negative sputum smears (adjusted prevalence ratio [aPR] 2.62, 95%CI 1.69–4.05), residence in three specific counties (aPR 1.71, 95%CI 1.19–2.46) and Black race (aPR 1.56, 95%CI 1.03–2.38).CONCLUSIONS: Nearly a quarter of TB patients at high risk of relapse did not receive extended treatment. Increased efforts are needed to ensure that all patients who may benefit from extended anti-tuberculosis treatment receive it.


  • Open Access

    Death With Tuberculosis in California, 1994–2008

    by Lisa Pascopella, Pennan M. Barry, Jennifer Flood, Kathryn DeRiemer

    Background. Identifying factors associated with tuberculosis (TB) deaths will inform efforts to prevent deaths.


  • Open Access

    Opportunities for Tuberculosis Diagnosis and Prevention among Persons Living with HIV: A Cross-Sectional Study of Policies and Practices at Four Large Ryan White Program-Funded HIV Clinics

    by Lisa Pascopella, Julie Franks, Suzanne M. Marks, Katya Salcedo, Kjersti Schmitz, Paul W. Colson, Yael Hirsch-Moverman, Jennifer Flood, Jennifer Sayles

    We describe the frequency and attributes of tuberculosis testing and treatment at four publicly-funded HIV clinics. We abstracted medical records from a random sample of 600 HIV-infected patients having at least one clinic visit in 2009 at four clinics in New York and Los Angeles Metropolitan Statistical areas. We described testing and treatment for tuberculosis infection (TBI), 2008–2010, and estimated adjusted odds ratios (aORs). We interviewed key informants and described clinic policies and practices. Of 600 patients, 500 were eligible for testing, and 393 (79%) were tested 2008–2010; 107 (21%) did not receive at least one tuberculin skin test or interferon gamma release assay. Results were positive in 20 (5%) patients, negative in 357 (91%), and unknown in 16 (4%). Fourteen (70%) of 20 patients with TBI initiated treatment at the clinics; only three were documented to have completed treatment. Three hundred twenty three (54%) patients had chest radiography, 346 (58%) had tuberculosis symptom screening, and three had tuberculosis disease (117 per 100,000 person-years, 95% confidence interval (CI) = 101–165). Adjusting for site, non-Hispanic ethnicity (aOR = 4.9, 95% CI = 2.6–9.5), and employment (aOR = 1.9, 95% CI = 1.0–3.4) were associated with TBI testing; female gender (aOR = 2.0, 95% CI = 1.4–3.3), non-black race (aOR = 1.7, 95% CI = 1.3–2.5), and unemployment (aOR = 1.5, 95% CI = 1.1–2.1) were associated with chest radiography. Clinics evaluated TBI testing performance annually and identified challenges to TB prevention. Study clinics routinely tested patients for TBI, but did not always document treatment. In a population with a high TB rate, ensuring treatment of TBI may enhance TB prevention.


  • Open Access

    When Tuberculosis Comes Back: Who Develops Recurrent Tuberculosis in California?

    by Lisa Pascopella, Kathryn DeRiemer, James P. Watt, Jennifer M. Flood

    Recurrent tuberculosis suggests potentially modifiable gaps in tuberculosis treatment and control activities. The frequency of late recurrences following treatment completion has not been well-studied. We determined the frequency of, and risk factors associated with, tuberculosis that recurs at least one year after completion of anti-tuberculosis therapy in California. The study population included culture-positive, pulmonary tuberculosis patients reported to the California tuberculosis case registry from 1993 to 2007 who completed anti-tuberculosis therapy. A person with late recurrent tuberculosis was defined as an individual that appeared in the registry more than once, determined by match on name and date-of-birth, with at least one year between treatment completion of the first episode and treatment initiation of the second episode. Among 23,517 tuberculosis patients, 148 (0.63%) had a late recurrence. Independent risk factors for recurrence included: infection with a pyrazinamide mono-resistant isolate (adjusted hazard ratio, 2.93; p = 0.019); initiation of an isoniazid- and rifampin-only treatment regimen (adjusted hazard ratio, 2.55; p = 0.0412); sputum smear-positive disease (adjusted hazard ratio, 1.96; p = 0.0003); human immunodeficiency virus infection (adjusted hazard ratio, 1.81; p = 0.0149); and birth in the United States (adjusted hazard ratio, 1.88; p = 0.0002). Infection with an isoniazid mono-resistant isolate was protective (adjusted hazard ratio, 0.25; p = 0.0171). The low frequency of late recurrent tuberculosis in California suggests that local TB control programs are largely successful at preventing this adverse outcome. Nonetheless, we identified subpopulations at increased risk of late tuberculosis recurrence that may benefit from additional medical or public health interventions.